Do you see a role for omidubicel upfront in severe aplastic anemia for patients without a matched donor?
In the trial by Childs et al., Blood 2025, patients also had to be unresponsive to IST, but given that it is now FDA-approved, would you consider it upfront in those eligible for transplant?
1 Answer
Mednet MemberInvited Expert
Hematology · Dana-Farber Cancer Institute
Answered on
We typically use cord blood products if there is no available family member donor or reasonably matched unrelated donor. The use of haploidentical family donors is very effective, less expensive, and allows supplementation with CD34+ stem cell boosts if counts are suboptimal DeZern et al., PMID 3234...
Join for free or sign in to see the full answer